 | |
 | |
| Clinical data | |
|---|---|
| Trade names | Fesobig , Toviaz |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a609021 |
| License data | |
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | 52% (active metabolite) |
| Protein binding | 50% (active metabolite) |
| Metabolism | Liver (CYP2D6- and3A4-mediated) |
| Eliminationhalf-life | 7–8 hours (active metabolite) |
| Excretion | Kidney (70%) and fecal (7%) |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| IUPHAR/BPS | |
| DrugBank |
|
| ChemSpider |
|
| UNII | |
| KEGG |
|
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.184.854 |
| Chemical and physical data | |
| Formula | C26H37NO3 |
| Molar mass | 411.586 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) (verify) | |
Fesoterodine (INN, used as thefumarate under the brand nameToviaz) is anantimuscarinic drug developed bySchwarz Pharma AG to treatoveractive bladder syndrome (OAB).[2] It was approved by theEuropean Medicines Agency in April 2007,[3] the USFood and Drug Administration on October 31, 2008[4] andHealth Canada on February 9, 2012.[5]
Fesoterodine is aprodrug. It is broken down into its active metabolite,desfesoterodine, by plasmaesterases.
Fesoterodine has the advantage of allowing more flexible dosage than othermuscarinic antagonists.[6] Its tolerability and side effects are similar to other muscarinic antagonists and as a new drug seems unlikely to make great changes in practices of treatment for overactive bladder.[6]
A Japanese study from 2017, showed that urgency and urge incontinence are improved after 3 days administration of the drug, with full efficacy able to be judged after 7 days administration. Overactive bladder was found to be resolved in 88% of patients after seven days usage.[7]
